

Now enrolling: the Phase 3 D1AMOND study for children, adolescents, and adults with Tourette's Disorder

A quick reference guide for patient advocacy groups

Thank you for your interest in learning about the Phase 3 D1AMOND study. This fact sheet provides study details that you can share with patients or their caregivers. If patients and/or caregivers have any questions or would like to know more, please direct them to call the local study site at the number below.

What is this study?

The Phase 3 D1AMOND study is a multicenter, randomized, double-blind study of children and adolescents 6 years of age and older and adults who have Tourette's Disorder.

The Phase 3 D1AMOND study is researching a study drug called ecopipam to evaluate how it works over time and how safe it is for children, adolescents, and adults with Tourette's Disorder.

Who is this study enrolling?

This study is enrolling participants who:

- Are at least 6 years of age
- Weigh at least 18 kg (39.6 lbs)
- Have been diagnosed with Tourette's Disorder
- Have both motor and vocal tics

This is not a complete list of study requirements. The study doctor will discuss all the requirements and answer any questions.

Why is this study important?

Tourette's Disorder affects millions of children, adolescents, and adults around the world. Currently approved therapies for Tourette's Disorder sometimes come with undesirable side effects, so there is a need for more research for this condition.

How long will this study last?

Participants will be in this study for approximately 8 months and will have at least 15 visits to the study site during that time. There will also be at least two telephone appointments during the study.

